Semaglutide sodium is a pharmaceutical compound employed in the treatment of type 2 diabetes. It belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, which are known for their ability to regulate blood sugar levels through various mechanisms. By functioning as a GLP-1 receptor agonist, it enhances insulin secretion from the pancreas, which helps to lower blood sugar levels. Additionally, it inhibits the secretion of glucagon, a hormone that raises blood sugar levels, and slows down the emptying of the stomach, which contributes to a more gradual and controlled release of glucose into the bloodstream. This multi-faceted approach to regulating blood sugar levels makes Semaglutide sodium an effective option in the management of type 2 diabetes. When administered through alternative routes, it has been shown to significantly improve glycemic control and reduce the risk of cardiovascular events in patients with diabetes.